[단독] 황상연 한미약품 대표 “R&D 강화…신동국 경영개입은 없어”

Hanmi Pharmaceutical's planned H2 2026 launch of epeglenatatide (HM11260C), a homegrown GLP-1 obesity drug, represents Korean pharma's breakthrough entry into a lucrative global market dominated by Western giants. With 20 years of R&D investment and aggressive licensing-out strategies alongside expanding R&D budgets, the company is positioning itself to compete globally while establishing sustainable revenue streams.